"A commitment is in place to provide 30 million vaccines in the fourth quarter (2020), so that in the first quarter (2021), we can vaccinate subjects," he noted during an online discussion in Jakarta, Tuesday.
Hartarto, concurrently chair of the Committee for Handling COVID-19 and National Economic Recovery (PEN), stated that the government had outlined a target for Indonesia to have access to between 250 million and 300 million doses of the COVID-19 vaccine by next year.
"The government has conducted clinical trials of the vaccines. The clinical trials were conducted not only in Indonesia but also in China, Brazil, Bangladesh, and Turkey. This is expected to be completed in December (2020)," he stated.
The minister explained that the target will be achieved through 10 sources comprising Sinovac, G-42/Wuhan Institute Biological Products/Sinopharm, Astra Zaneca, GAVI/CEPI, and CanSino Biological Inc./Beijing Institute Technology.
"The vaccine from GAVI/CEPI is estimated to be priced lower by around US$3 to US$5, while the Sinovac vaccine is projected to cost between US$10 and US$20," he revealed.
Others are the BioNTech/Fosun Pharma/Pfizer, Modena/NIAID (National Institute of Allergy and Infection Diseases, Acturus Therapeutics/Duke-NUS, Genexine Korea, and Red and White Vaccine.
"The development of our own vaccine -- Red and White Vaccine -- is expected to enter the third phase in the middle or third quarter of 2021," he remarked.
Hartarto noted that vaccines administered to the public would be different since some vaccines necessitated only one injection, while some were injected twice.
"Some vaccines are administered once and twice. Sinovac seems to be twice. The Sinopharm vaccine is estimated to be given once, so the method and pricing will be different," he added.
Related news: Indonesia explores cooperation with several vaccine producers
Related news: Indonesia to obtain 30 million COVID-19 vaccine doses at 2020-end EDITED BY INE